基石药业-B(02616.HK) 公布,舒格利单抗(择捷美)GEMSTONE-303研究结果在医学期刊《美国医学会杂志》(JAMA)主刊正式发表。
舒格利单抗是全球首个获批用于胃/胃食管结合部(G/GEJ)腺癌的PD-L1单抗。(ha/da)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.